Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs

Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs

Metropolis Healthcare reports Q1 FY26 PAT higher by 19% at Rs. 45 Cr

Biocon Foundation and IISc commemorate World Head & Neck Cancer Day

This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines

10.18 Cr women screened for cervical cancer under Govt. schemes

This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases

ImCheck’s ICT01 receives FDA ODD for treatment of acute myeloid leukemia

Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials

WHO, ITU, and WIPO release new report on AI use in traditional medicine

The global TCIM market is expected to reach nearly US$ 600 billion by 2025

FDA approves Bravecto Quantum from Merck Animal Health

Biocon Biologics receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars

Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone

AbbVie announces new data demonstrating Atogepant achieves superiority in Phase 3 study

TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month

Bayer’s Sevabertinib granted FDA priority review for the treatment of patients with HER2-mutant non-small cell lung cancer

This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition